The brain-penetrant clinical ATM inhibitor AZD1390 radiosensitizes and improves survival of preclinical brain tumor models

Poor survival rates of patients with tumors arising from or disseminating into the brain are attributed to an inability to excise all tumor tissue (if operable), a lack of blood-brain barrier (BBB) penetration of chemotherapies/targeted agents, and an intrinsic tumor radio-/chemo-resistance. Ataxia-...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Sci Adv
Main Authors: Durant, Stephen T., Zheng, Li, Wang, Yingchun, Chen, Kan, Zhang, Lingli, Zhang, Tianwei, Yang, Zhenfan, Riches, Lucy, Trinidad, Antonio G., Fok, Jacqueline H. L., Hunt, Tom, Pike, Kurt G., Wilson, Joanne, Smith, Aaron, Colclough, Nicola, Reddy, Venkatesh Pilla, Sykes, Andrew, Janefeldt, Annika, Johnström, Peter, Varnäs, Katarina, Takano, Akihiro, Ling, Stephanie, Orme, Jonathan, Stott, Jonathan, Roberts, Caroline, Barrett, Ian, Jones, Gemma, Roudier, Martine, Pierce, Andrew, Allen, Jasmine, Kahn, Jenna, Sule, Amrita, Karlin, Jeremy, Cronin, Anna, Chapman, Melissa, Valerie, Kristoffer, Illingworth, Ruth, Pass, Martin
Formato: Artigo
Idioma:Inglês
Publicado em: American Association for the Advancement of Science 2018
Assuntos:
Research Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6010333/
https://ncbi.nlm.nih.gov/pubmed/29938225
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1126/sciadv.aat1719
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados